Universidad Nacional de Asunción investigates tirzepatide in Paraguay

The Department of Endocrinology and Metabolism at the Hospital de Clínicas, part of the Universidad Nacional de Asunción (UNA) Faculty of Medicine, is conducting an observational Phase IV research project. The study aims to evaluate the safety and effectiveness of tirzepatide in Paraguayan patients living with obesity, with or without type 2 diabetes mellitus.

Led by Dr. Ana Iris Ramírez, the research will analyze the drug's effects under real-world clinical conditions to generate local post-marketing pharmacovigilance evidence. The primary objective is to document the drug's safety profile over 12 months, focusing on the incidence and severity of adverse events. Secondary objectives include assessing weight reduction, body mass index (BMI) changes, and improvements in metabolic parameters such as glucose, HbA1c, and lipid profiles.

Participants are recruited from the Obesity Unit in San Lorenzo. Inclusion criteria require patients to be over 18 years old with a BMI of 35 or higher who have not previously used tirzepatide. The study also monitors patient tolerance, adherence, and satisfaction.